Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Kanawha Capital Management LLC

Kanawha Capital Management LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 86,411 shares of the medical instruments supplier’s stock after selling 266 shares during the quarter. Becton, Dickinson and Company comprises approximately 1.5% of Kanawha Capital Management LLC’s portfolio, making the stock its 18th largest holding. Kanawha Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $20,834,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company during the 3rd quarter valued at approximately $26,000. Sound Income Strategies LLC lifted its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Opal Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company in the 2nd quarter valued at $45,000. Abound Wealth Management increased its stake in Becton, Dickinson and Company by 96.0% in the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 96 shares during the period. Finally, Chilton Capital Management LLC raised its position in Becton, Dickinson and Company by 1,233.3% during the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 185 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BDX. Raymond James dropped their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Evercore ISI lifted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus increased their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $235.24 on Monday. The firm has a market capitalization of $67.99 billion, a PE ratio of 48.40, a P/E/G ratio of 1.75 and a beta of 0.43. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $259.92. The firm’s 50-day simple moving average is $237.56 and its 200 day simple moving average is $235.09. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same period in the prior year, the business earned $2.96 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. On average, equities research analysts predict that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.